A-2021-000129

A-2021-000129 is the reference number for a completed FOI request from the Public Health Agency of Canada (PHAC). It focuses primarily on a series of e-mail communications between PHAC employees in regards to how to handle communications around ivermectin and public requests for its use to treat COVID-19.

Request details

Date Records Requested Request No. Response Letter Disclosure Package Notes
April 2022 All communication regarding the use of Ivermectin in the treatment of Covid-19. Date range March 1, 2020 to June 7, 2021. A-2021-000129 - Disclosure -

People

The following table outlines the individuals involved in the discussions/materials included in the document release.

Name Affiliation Position Notes
Kristian Andersen Scripps Research Institute - -
Jacqueline Arthur Public Health Agency of Canada, Centre for Communicable Disease and Infection Control Senior Manager, AMR Division On page 17 of the disclosure, she comments on the membership of the Front Line COVID-19 Critical Care Alliance (FLCCC) saying, “Interesting membership, all white males…”
Mina Azad Public Health Agency of Canada, Centre for Communicable Disease and Infection Control Research Analyst, COVID-19 Therapeutics PhD biochemist
Lizanne Beique Public Health Agency of Canada Senior Policy Analyst -
Serena Cortés-Kaplan Public Health Agency of Canada, COVID-19 Therapeutics, Centre for Communicable Disease and Infection Control Student Analyst -
Adéle Croteau Public Health Agency of Canada Issues Manager - COVID-19 Therapeutics1) -
Jaahnavi Dave Public Health Agency of Canada - Researcher under BioCanRx, a Pfizer-funded network. Also published research on a COVID-19 vaccine candidate while working with PHAC and early treatment denial.
Joseph Djiometio Public Health Agency of Canada, Centre for Communicable Disease and Infection Control Technical Lead, COVID-19 Therapeutics -
Laurent Duvernay-Tardif - - -
Bersabel Ephrem Public Health Agency of Canada, Centre for Communicable Disease and Infection Control Director General -
Nicole Forbes Public Health Agency of Canada, National Advisory Committee on Immunization (NACI), Centre for Immunization Readiness2) Scientific Project Coordinator Alumni of BioCanRx
Stephan Gadient Public Health Agency of Canada - -
Margaret Gale-Rowe Public Health Agency of Canada - -
Shalane Ha Public Health Agency of Canada - -
Emma Hodcroft CoVariants, Institute of Social and Preventive Medicine, SIB Swiss Insitute of Bioinformatics - Signatory to the John Snow Memorandum
Linsey Hollett Health Canada - -
Kelly Hunt Public Health Agency of Canada - -
Marium Jamil Public Health Agency of Canada, Office of the Chief Science Officer Policy Analyst -
Anna Jirovec - - -
Marita Killen Public Health Agency of Canada - -
Pierre Kory Front Line COVID-19 Critical Care Alliance (FLCCC) - Contacted Andrew Morris to “spew anger” and advise Morris that he would be proven wrong about ivermectin.
Niyi Lawuyi Public Health Agency of Canada COVID-19 Therapeutics Team, Advisor to Director General3) -
Kaili Levesque Health Canada, Public Health Agency of Canada Vice President, COVID-19 Vaccine Rollout -
Erika Lingohr Public Health Agency of Canada Researcher -
Syra Madad - - Developed a “cheat sheet” that included staying home, wearing a mask, social distancing, avoiding crowds, close contact or confined spaces, opening windows, washing hands, cleaning high-touch surfaces, complying with contact tracing, listening to public health for updates, getting tested for SARS-CoV-2 periodically, getting transfected with a COVID-19 vaccine, monitoring for symptoms of COVID-19, and covering coughs/sneezes.
Jonathan Mahdi Health Canada - -
Cheryl Marisnky Public Health Agency of Canada - -
Hollie McLean Health Canada - -
Andrew Morris Ontario COVID-19 Science Advisory Table, University of Toronto, Sinai Health System, University Health Network - Writes “COVID Emails” newsletter. Chair of the Behavioural Science Working Group of the Ontario COVID-19 Science Advisory Table. Recommended his readers go outside and get sunlight.
Howard Njoo Public Health Agency of Canada Deputy Chief Public Health Officer -
Pamela Ponic Public Health Agency of Canada - -
Celisse Poon Young Public Health Agency of Canada Scheduling Assistant4) -
Angela Rasmussen - - Developed a “cheat sheet” that included staying home, wearing a mask, social distancing, avoiding crowds, close contact or confined spaces, opening windows, washing hands, cleaning high-touch surfaces, complying with contact tracing, listening to public health for updates, getting tested for SARS-CoV-2 periodically, getting transfected with a COVID-19 vaccine, monitoring for symptoms of COVID-19, and covering coughs/sneezes.
Marina Salvadori Public Health Agency of Canada - Briefs Theresa Tam on “all things scientific”
Elaha Sarwar Public Health Agency of Canada - -
Jennifer Siushansian Public Health Agency of Canada - -
Theresa Tam Public Health Agency of Canada Chief Public Health Officer -
Karen Timmerman Public Health Agency of Canada - -
Lisa Waddell Public Health Agency of Canada - -
Redacted Alberta Health - -

Organizations

Therapeutics

Common name Brand name Other names Company Notes
Anakinra Kineret - Swedish Orphan Biovitrum (Sobi) -
Aspirin - - - -
Baricitinib Olumiant - Incyte, Eli Lilly -
Chloroquine - - - Not recommended in any context for COVID-19 by Health Canada
Colchicine Colcrys, Mitigare, others - - -
Convalescent plasma - - - -
Dexamethasone - - - -
Fluvoxamine - - - -
Hydroxychloroquine - - - Not recommended in any context for COVID-19 by Health Canada
Interferon - - - Not recommended in any context for COVID-19 by Health Canada
Ivermectin Stromectol, Mectizan - Merck Administered intravenously (IV) and orally in studies for the treatment of COVID-19. Authorized by Health Canada for the treatment of parasitic infections in humans and animals. Indicated in humans for the treatment of intestinal strongyloidiasis and onchoceriasis/rosacea. Not recommended for use outside of clinical trials.
Melatonin - - - -
Molnupiravir - MK-4482 Merck, Ridgeback Pharmaceuticals -
Lopinavir/ritonavir Kaletra - AbbVie HIV/AIDS drug
Quercetin - - - -
Remdesivir Veklury GS-5734 Gilead Sciences -
Vitamin C - Ascorbic acid, ascorbate - -
Vitamin D - - -
Zinc - - - -
Monoclonal antibodies
Tixagevimab/cilgavimab Evushield AZD7442 AstraZeneca -
Bamlanivimab - - AbCellera, Eli Lilly -
Casirivimab and/or imdevimab - - Regeneron, Genentech -
Otilimab - - GlaxoSmithKline -
Sarilumab Kevzara - Sanofi, Regeneron -
Tocilizumab Actemra - Roche -

Protocols

Clinical Trials

Trial Number Name Sponsor Principal Investigator
NCT04527211 Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel (IveprofCovid19) Javeriana University Eduar Echeverri
NCT04405843 Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19 (EPIC Trial) Centro de Estudios en Infectogía Pediatrica Eduardo López-Medina
NCT04529525 Ivermectin to Prevent Hospitalizations in COVID-19 (IVERCORCOVID19) Instituto de Cardiología de Corrientes Rodrigo Zoni, Julio Vallejos
2)
Where Are They Now: Nicole Forbes. (2020, November 20). BioCanRx. https://web.archive.org/web/20230316080334/https://biocanrx.com/now-nicole-forbes
4)
Celisse Poon Young · Public Health Agency of Canada · Scheduling Assistant. OpenGovCA. Retrieved March 19, 2023, from https://web.archive.org/web/20230319202032/https://opengovca.com/employee/celisse-poon-young
Back to top